A Phase I/Ib Study of the PD-1 Antibody Pembrolizumab in Combination With Ibrutinib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 29 Jul 2019 Status changed from active, no longer recruiting to completed.
- 02 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2017 Status changed from not yet recruiting to recruiting.